

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA: Ozanimod for treating relapsing–remitting multiple sclerosis

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal determination

- | |
|--|
| 1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these? |
|--|

One public commentator noted that multiple sclerosis is a disabling condition and limiting patient choice may contribute towards inequalities amongst people with multiple sclerosis who are disabled.
--

However, the NICE recommendation is no more or less favourable depending on whether a person has a disability. Accordingly, this is not an equality issue that needed to be discussed by the committee.

- | |
|--|
| 2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group? |
|--|

N/A (no change to recommendations)

- | |
|---|
| 3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability? |
|---|

N/A (no change to recommendations)

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

N/A (no change to recommendations)

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

N/A (not described in FAD)

Approved by Associate Director (name): Henry Edwards

Date: 13/05/2021